Ukr.Biochem.J. 2015; Volume 87, Issue 3, May-Jun, pp. 31-36


Furin inhibitors based on the derivatives of calix[4]arene CX3im

V. K. Kibirev1, T. V. Osadchuk2, R. V. Rodik3, V. I. Kalchenko3

1Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv;
2Institute of Bioorganic Chemistry and Petrochemistry, National Academy
of Sciences of Ukraine, Kyiv;
3Institute of Organic Chemistry, National Academy of Sciences of Ukraine, Kyiv

The aim of this work was to study antifurin activity of some derivatives of calix[4]arenes modified on the upper rim of the macrocycle by positively charged or uncharged groups. It was found that calixarene CX3im­ derivatives containing positively charged N-methylimidazolium cycles were indeed able to inhibit furin (Ki = 58.2 μM). The magnitude of the effects depended also on the hydrophobicity of the substituents located on the lower rim of the macrocycle. The  findings indicated the possibility of creating furin inhibitors of new generation based on the calix[4]arene platform.

Keywords: , ,


  1. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol. 2002 Oct;3(10):753-66. Review. PubMed, PubMedCentral, CrossRef
  2. Kibirev VK, Osadchuk TV, Radavskii IuL. Furin and its biological role. Ukr Biokhim Zhurn. 2007 Nov-Dec;79(6):5-18. Review. Russian. PubMed
  3. Seidah NG. The proprotein convertases, 20 years later. Methods Mol Biol. 2011;768:23-57. PubMed, CrossRef
  4. Chretien M, Seidah NG, Basak A, Mbikay M. Proprotein convertases as therapeutic targets. Expert Opin Ther Targets. 2008 Oct;12(10):1289-300. PubMed, CrossRef
  5. Basak A. Inhibitors of proprotein convertases. J Mol Med (Berl). 2005 Nov;83(11):844-55.  Review. PubMed, CrossRef
  6. Kibirev VK, Osadchuk TV. Structure and properties of proprotein convertase inhibitors. Ukr Biokhim Zhurn. 2012 Mar-Apr;84(2):5-29. PubMed
  7. Utpal Chandra De, Priyambada Mishra, Prasenjit Rudra Pal, Biswanath Dinda, Ajoy Basak. Non-peptide inhibitors of proprotein convertase  subtilisin kexins (PCSKs). An overall review of existing and new data. (ed. Majid Khatib). Colloquium Series on Protein Activation and Cancer. 2012;1(3):1-76.
  8. Hosaka M, Nagahama M, Kim WS, Watanabe T, Hatsuzawa K, Ikemizu J, Murakami K, Nakayama K. Arg-X-Lys/Arg-Arg motif as a signal for precursor cleavage catalyzed by furin within the constitutive secretory pathway. J Biol Chem. 1991 Jul5;266(19):12127-30. PubMed
  9.  Becker GL, Lu Y, Hardes K, Strehlow B, Levesque C, Lindberg I, Sandvig K, Bako­wsky U, Day R, Garten W, Steinmetzer T. Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases. J Biol Chem. 2012;287(26):21992-22003. PubMed, PubMedCentral, CrossRef
  10. Jiao G-S, Cregar L, Wang J, Millis SZ, Tang C, O’Malley S, Johnson AT, Sareth S, Larson J, Thomas G. Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine. Proc Natl Acad Sci USA. 2006 Dec 26;103(52):19707-12. PubMed, PubMedCentral, CrossRef
  11. Sielaff F, Than ME, Bevec D, Lindberg I, Steinmetzer T. New furin inhibitors based on weakly basic amidinohydrazones. Bioorg Med Chem Lett. 2011 Jan 15;21(2):836-40.  PubMed, CrossRef
  12. Kibirev VK, Osadchuk TV, Vadzyuk OB, Kozachenko OP, Brovarets VS. Non-peptide furin inhibitors based on amidinohydrazones of diarylaldehydes. Ukr Biokhim Zhurn. 2013 Jan-Feb;85(1):22-32. PubMed, CrossRef
  13. López-Vallejo F, Martínez-Mayorga K. Furin inhibitors: importance of the positive formal charge and beyond. Bioorg Med Chem. 2012 Jul 15;20(14):4462-71.  PubMed, CrossRef
  14. Gutsche CD. Calixarenes Revisited. Ed.: J. F. Stoddart. The Royal Society of Chemistry: Cambridge, 1998. CrossRef
  15. Fahlbusch T, Frank M, Schatz J, Schmaderer H. Influence of the number and geometry of binding sites on host-guest affinity: Imidazolium-substituted receptor molecules for small inorganic anions. Eur J Org Chem. 2006;(8):1899-1903. CrossRef
  16. Mchedlov-Petrossyan NO, Vilkova LN, Vodolazkaya NA, Yakubovskaya AG, Rodik RV, Boyko VI, Kalchenko VI. The nature of aqueous solutions of a cationic calix[4]arene: a comparative study of dye–calixarene and dye–surfactant interactions. Sensors. 2006;6(8):962-977. CrossRef
  17. Rodik RV, Klymchenko AS, Jain N, Miroshnichenko SI, Richert L, Kalchenko VI, Mély Y. Virus-sized DNA nanoparticles for gene delivery based on micelles of cationic calixarenes. Chemistry. 2011 May 9;17(20):5526-38. Epub 2011 Apr 18. PubMedCrossRef
  18. Saberov VS, Marichev KO, Korotkikh MI, Shvaika OP, Rodik RV, Drapailo АB, Pekhtereva TM, Komarovska-Porokhnya­vets OZ, Lubenets VI, Novikov VP. Synthesis and the antimicrobial activity of precarbene and metalcarbene compounds of the imidazole series. J Org Pharm Chem. 2014;12(2):36-43.
  19. Boyko V, Rodik R, Danylyuk O, Tsymbal L, Lampeka Y, Suwinska K, Lipkowski J, Kalchenko V. Tetrazolecalix[4]arenes as new ligands for palladium (II). Tetrahedron. 2005;61(52):12282-12287. CrossRef
  20. Rodik R, Rozhenko AB, Boyko V, Piro­zhenko VV, Danylyuk O, Suwin­ska K, Lipkowski J, Kalchenko V. Calix[4]arene­quinazolinones. Synthesis and structure. Tetrahedron. 2007;63(46):11451-11457.
  21. Mutihac L, Lee JH, Kim JS, Vicens J. Recognition of amino acids by functionalized calixarenes. Chem Soc Rev. 2011 May;40(5):2777-96. Review. PubMed, CrossRef
  22. Sliwa W., Kozlowsky C. Calixarene and resorcinarenes. Wiley, 2009; 324 p.
  23. Nimse SB, Kim T. Biological applications of functionalized calixarenes. Chem Soc Rev. 2013 Jan 7;42(1):366-86. Review. Erratum in: Chem Soc Rev. 2012 Dec 21;41(24):8212. PubMed, CrossRef
  24. de Fátima A, Fernandes SA, Sabino AA. Calixarenes as new platforms for drug design. Curr Drug Discov Technol. 2009 Jun;6(2):151-70. Review.  PubMedCrossRef

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.